Transvenous Embolization in Patients with Dural Arteriovenous Fistula.
10.3348/jkrs.2005.53.4.245
- Author:
Eun Ju LEE
1
;
Woong YOON
;
Jeong Jin SEO
;
Sang Soo SHIN
;
Hyo Soon LIM
;
Sang Gook SONG
;
Nam Gyu JANG
;
Suk Hee HEO
;
Heoung Keun KANG
Author Information
1. Department of Radiology, Chonnam National University Medical School, Korea. radyoon@cnuh.com
- Publication Type:Original Article
- Keywords:
Fistula, therapeutic embolization;
Veins, therapeutic embolization;
Fistula, arteriovenous;
Arteriovenous malformations, dural;
Sinuses, dural
- MeSH:
Arteriovenous Fistula;
Cavernous Sinus;
Central Nervous System Vascular Malformations*;
Classification;
Colon, Sigmoid;
Endovascular Procedures;
Female;
Follow-Up Studies;
Humans;
Male;
Medical Records;
Platinum;
Recurrence;
Retrospective Studies
- From:Journal of the Korean Radiological Society
2005;53(4):245-251
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the efficacy of transvenous embolization in patients with dural arteriovenous fistula (DAVF). MATERIALS AND METHODS: From October 2002 to July 2004, eight patients with angiographically confirmed DAVF underwent transvenous embolization of the affected dural sinuses. Concomitant transarterial embolization was performed in four patients. Patients included five men and three women aged 45-78 years (mean age, 55.4 years). The patient's medical records and angiographic features were retrospectively reviewed. Patients had follow-up periods ranging from 5 to 24 months (mean, 16.5 months). RESULTS: The locations of DAVF were transverse - sigmoid sinus in six patients and cavernous sinus in two patients. According to Cognard's classification, four of the DAVFs were Type I, two were type IIa, and two were Type IIb. Embolic materials used for the transvenous embolization were platinum detachable coils and fibered microcoils. After the transvenous embolization, there was complete obliteration of the DAVF in seven patients and significant flow reduction in one patient. All cases were clinically successful. There were no transient or permanent complications as a result of the endovascular procedures in any of the patients. One patient who had symptom recurrence 2 months after the initial treatment was successfully treated with repeated transvenous embolization. The remaining seven patients had no symptom recurrence during the follow-up period. CONCLUSION: Transvenous embolization is an effective and safe method in the treatment of patients with DAVF.
